Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;20(11):1373-1384.
doi: 10.1007/s12094-018-1891-7. Epub 2018 May 24.

Cutaneous toxicities of new treatments for melanoma

Affiliations
Review

Cutaneous toxicities of new treatments for melanoma

A Boada et al. Clin Transl Oncol. 2018 Nov.

Abstract

New drugs against advanced melanoma have emerged during last decade. Target therapy and immunotherapy have changed the management of patients with metastatic disease. Along with its generalized use, drug toxicities have appeared and the skin is the target organ of a significant part of them. This revision summarizes the most common side effects and consensus management to improve the compliance of therapies and patients' quality of life. Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma. Special attention must be paid to the development of new primary melanomas or changes on nevi during BRAF inhibitor therapy. The most common cutaneous side effects of immunotherapy are rash, pruritus, and vitiligo. It remains controversial the possible role of these toxicities as markers of response to therapy.

Keywords: Immunotherapy; Melanoma; Nivolumab; Pembrolizumab; Target therapy; Toxicity.

PubMed Disclaimer

References

    1. J Clin Oncol. 2008 Dec 20;26(36):5950-6 - PubMed
    1. Br J Dermatol. 2015 Jan;172(1):239-43 - PubMed
    1. Eur J Dermatol. 2015 Sep-Oct;25(5):452-6 - PubMed
    1. J Am Acad Dermatol. 2012 Dec;67(6):e275-6 - PubMed
    1. J Am Acad Dermatol. 2012 Dec;67(6):1265-72 - PubMed

MeSH terms

LinkOut - more resources